Secondary Logo

Journal Logo

RESEARCH LETTERS

Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen

Badiou, Stéphaniea; De Boever, Corinne Merleb; Dupuy, Anne-Mariea; Baillat, Vincentb; Cristol, Jean-Paula; Reynes, Jacquesb

Author Information

In order to characterize the influence of a lopinavir/ritonavir-containing regimen on the lipoprotein profile, lipid parameters and LDL size, as an index of atherogenicity, were determined in 24 HIV-infected adults before and after the initiation of lopinavir/ritonavir treatment. At baseline an abnormal prevalence of small dense LDL was observed. One month of lopinavir/ritonavir use enhanced triglyceride and apolipoprotein CIII levels and reduced LDL size, suggesting an increase in atherogenicity.

The changes in the lipid metabolism of HIV patients have raised clinical concern with respect to the atherogenic risk [1,2]. As well as cholesterol, hypertriglyceridemia appears to be an independent risk factor partly by the occurrence of small dense LDL [3]. Indeed, small dense LDL have a greater capacity to infiltrate the arterial wall, a reduced affinity for the LDL receptors and an increased susceptibility to ex-vivo oxidation [4]. Recently, a high prevalence of small dense LDL in HIV patients was reported [5]. The determination of LDL size could thus be a useful tool to assess the atherogenic risk in HIV patients.

A lopinavir/ritonavir-containing regimen was initiated in 24 consecutive HIV-infected adults who were in virological failure or therapeutic intolerance. All the patients were evaluated before the initiation of lopinavir/ritonavir and at one month thereafter. Fourteen HIV-uninfected controls matched for age and body mass index were enrolled. All individuals provided inform consent and none took lipid-lowering drugs. Venous blood samples were collected after an overnight fast. Total cholesterol and triglyceride levels were measured using routine enzymatic methods. Apolipoprotein (apo) A1, B and CIII measurements were performed using an immunonephelometric assay. The size of the predominant LDL subfraction was determined by plasma electrophoretic migration in polyacrylamide gradient gels.

Most patients (88%) were in the symptomatic stage, none had acute opportunistic infections, and 58% were suffering from lipodystrophy. All patients were treatment-experienced, with a mean duration of 60 months’ exposure to highly active antiretroviral therapy (HAART) and 28 months’ exposure to protease inhibitors (PI). Fourteen patients were in therapeutic interruption of at least 2 months, motivated by virological failure. The remaining 10 patients were currently receiving HAART.

Significantly higher triglyceride levels, lower apoA1 levels and a smaller mean LDL size were observed in HIV patients when compared with controls (Table 1). No difference was observed between patients with or without lipodystrophy. The presence of small dense LDL (< 25.5 nm) was observed in 75% of HIV patients compared with 7% in the control group. One month of a lopinavir/ritonavir-containing regimen resulted in a significant increase in total cholesterol, triglyceride, apoA1, B and CIII levels, associated with a significant reduction in LDL size. The prevalence of hypertriglyceridemia (> 2 mmol/l) increased from 54% at baseline to 79%. An elevation of triglyceride levels was correlated with an increase in apoCIII (r = 0.84).

Table 1
Table 1:
Lipid parameters and LDL size.

Evidence is emerging that the incidence of cardiovascular events has increased over the past few years in HIV-infected adults [6,7], and HAART-induced or worsened dyslipidemia has been suggested to be an independent risk factor [1,8]. In our study an atherogenic lipid profile including a high prevalence of small dense LDL was evidenced at baseline. This atherogenic profile appears to be majored under a lopinavir/ritonavir-containing regimen by a more reduced LDL size.

The mechanisms involved in HAART-induced hypertriglyceridemia remain unclear but apoCIII, an endogenous inhibitor of lipoprotein lipase, seems to play a pivotal role. Under PI administration, an increase in apoCIII levels and more particularly apoCIII associated with apoB-containing lipoparticles, was previously described [9]. In agreement with these data, we observed a global positive correlation between triglyceride levels and apoCIII levels (r = 0.88). The impairment of lipoprotein lipase leads to VLDL accumulation, hypertriglyceridemia and the occurrence of the atherogenic small dense LDL [10], which were previously reported in HIV patients [5].

Few data have been published on lipid and lipoprotein changes during lopinavir/ritonavir therapy. In antiretroviral-naive and PI-experienced patients a significant increase in mean cholesterol and triglyceride levels was described, but without respect to fasting [11–13].

In our study, a lopinavir/ritonavir-containing regimen accentuated HIV-induced dyslipidemia by an important increase in triglyceride and apoCIII levels associated with a reduction in LDL size, leading to an atherogenic profile.

As fibrates lower triglyceride and apoCIII levels [9], and increase LDL size [14], they appear to be a logical option to manage HAART-induced dyslipidemia.

References

1.Periard D, Teleni A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.Circulation 1999, 100:700–705.
2.Seminari E, Pan A, Voltini G, Carnevale G, Maserati R, Minoli L, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors.Atherosclerosis 2002, 162:433–438.
3.St-Pierre AC, Ruell IL, Cantin B, Dagenais GR, Bernard PM, Despres JP, et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic disease.Circulation 2001, 104:2295–2299.
4.Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.Eur Heart J 1998, 19 (Suppl. A):A24–A30.
5.Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.Circulation 2001, 104:257–262.
5.Leport C, Saves M, Ducimetiere P, Le Moal G, Amouyel P, Arveiler D, et al. Coronary heart disease risk (CHD) in French HIV-infected men started on a protease inhibitor (PI)-containing regimen compared to the general population. In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [Abstract 697T].
7.Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?.J Acquir Immune Defic Syndr 2002, 30:471–477.
8.Smith JH, Martin GJ, Decker CF. Hyperlipidemia associated with the use of protease inhibitors.Clin Infect Dis 2000, 31:207–208.
9.Bonnet E, Ruidavets JB, Tuech J, Ferrieres J, Collet X, Fauvel J, et al. Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy.J Clin Endocrinol Metab 2001, 86:296–302.
10.Schmitz M, Michl GM, Walli R, Bogner J, Bedynek A, Seidel D, et al. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy.J Acquired Immune Defic Syndr 2001, 26:225–235.
11.Murphy RL, Brun S, Hicks C, Er Eron JJ, Gulick R, King M, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.AIDS 2001, 15:1–9.
12.Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.J Infect Dis 2002, 185:599–607.
13.Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir–ritonavir versus nelfinavir for the initial treatment of HIV infection.N Engl J Med 2002, 346:2039–2046.
14.Lemieux I, Laperrière L, Dzavik V, Tremblay G, Bourgeois J, Despres JP. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.Atherosclerosis 2002, 162:363–371.
© 2003 Lippincott Williams & Wilkins, Inc.